Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.
about
Management of Mycoplasma genitalium infections - can we hit a moving target?Antibiotics in the clinical pipeline at the end of 2015.Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus.Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid.In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United StatesThe good, the bad and the tasty: The many roles of mushrooms.Pleuromutilins: Potent Drugs for Resistant Bugs-Mode of Action and Resistance.New antibiotics for bad bugs: where are we?New antibacterial agents: patent applications published in 2011.Fungal natural products in research and development.Natural product and natural product derived drugs in clinical trials.Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium.Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon.In vitro activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively-drug resistant Neisseria gonorrhoeae.A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism.Mycoplasma genitalium infections: current treatment options and resistance issues.Biosynthetic Machinery of Diterpene Pleuromutilin Isolated from Basidiomycete Fungi.In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens.
P2860
Q26796722-863B2D6B-6006-4E87-B8E2-D87F57550283Q30249262-6FAB4704-A2C2-4713-91FA-6957360C2531Q34497915-B9A6239D-B6A6-4275-B766-13931F299C69Q34508161-7A9E5B2E-61DF-4607-8CB7-DC747EF70489Q34525879-A0EEF2AD-F2F6-48CD-856B-48F803FBA40EQ37570744-4E125916-D307-4B51-A927-FFC2FBC12E87Q37835585-D280F8C2-295E-4189-9BDB-46FE8246BD07Q38132217-A4511729-6491-414E-BC08-5D951E9CC616Q38172657-95E8C706-1B0D-43E2-ACF0-BF9F9BE9DA19Q38239799-67DA0AB5-A555-4D04-AEA0-07AF29F25318Q38247457-267ECC3E-01FF-4688-9285-B845D98EBD4BQ38772340-A2A8F095-68DF-4D01-A0EA-C3C3C046DE41Q39362169-9E088F57-3D12-4453-A552-002EE908C6D5Q40052692-2520FDD8-472D-433D-94E6-D90819A2F22FQ41872353-3C0A6D8F-C9DF-4921-9331-1848C27AA7C8Q42355223-C8C86063-6AA1-43A2-B844-4D90E87C9DB5Q47780684-D2D666FC-DB87-427C-9200-867F7979A227Q52659745-976F43CE-86FC-466D-A437-16DAB99D15BC
P2860
Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Phase II clinical study of BC- ...... and skin structure infections.
@en
type
label
Phase II clinical study of BC- ...... and skin structure infections.
@en
prefLabel
Phase II clinical study of BC- ...... and skin structure infections.
@en
P2093
P2860
P356
P1476
Phase II clinical study of BC- ...... and skin structure infections.
@en
P2093
F Obermayr
G H Talbot
W T Prince
Z Ivezic-Schoenfeld
P2860
P304
P356
10.1128/AAC.02106-12
P407
P577
2013-02-19T00:00:00Z